Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 1/20 | 0.58 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.58 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.58 |
| ▸ | MAOA | P21397 | 1/20 | 0.58 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.58 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.58 |
| ▸ | MDH1 | P40925 | 1/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.58 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.58 |
| ▸ | HRH4 | Q9H3N8 | 5/20 | 0.55 |
| ▸ | PARP1 | P09874 | 1/20 | 0.51 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.48 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.48 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.48 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.48 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.48 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.48 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | SYK | P43405 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Atevirdine Mesylate SCHEMBL29377031 | 0.88 | HRH4 (0.57) | ADRA2AADORA3CHRM1MAOATBXA2R | |
| Atevirdine Mesylate SCHEMBL29365699 | 0.88 | HRH4 (0.57) | ADRA2AADORA3CHRM1MAOATBXA2R | |
| Atevirdine Mesylate SCHEMBL356038 | 0.88 | HRH4 (0.57) | ADRA2AADORA3CHRM1MAOATBXA2R | |
| Atevirdine Mesylate SCHEMBL146999 | 0.85 | ADRA2A (0.59) | ADRA2AADORA3CHRM1MAOATBXA2R | |
| Atevirdine Mesylate SCHEMBL29636966 | 0.85 | ADRA2A (0.59) | ADRA2AADORA3CHRM1MAOATBXA2R | |
| SCHEMBL18329597 | 0.83 | ADRA2A (0.51) | ADRA2AADORA3CHRM1MAOATBXA2R | |
| SCHEMBL8985882 | 0.81 | PARP1 (0.49) | ADRA2AADORA3CHRM1MAOATBXA2R | |
| SCHEMBL8924496 | 0.80 | ADRA2A (0.58) | ADRA2AADORA3CHRM1MAOATBXA2R | |
| SCHEMBL12494603 | 0.80 | ADRA2A (0.77) | ADRA2AADORA3CHRM1MAOATBXA2R | |
| SCHEMBL8793755 | 0.78 | ADRA2A (0.55) | ADRA2AADORA3CHRM1MAOATBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 213 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210008104-A1 | COMPOSITIONS AND METHODS FOR INHIBITING HIV-1 REVERSE TRANSCRIPTASE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2021-01-14 | — | — | US | claimed |
| EP-3664811-A2 | COMPOSITIONS AND METHODS FOR INHIBITING HIV-1 REVERSE TRANSCRIPTASE | The U.S.A. as represented by the Secretary, Department of Health and Human Services (US) | 2020-06-17 | — | — | EP | claimed |
| CN-111163783-A | Compositions and methods for inhibiting HIV-1 reverse transcriptase | 美国政府卫生与公众服务部 | 2020-05-15 | — | — | CN | claimed |
| WO-2019032749-A2 | COMPOSITIONS AND METHODS FOR INHIBITING HIV-1 REVERSE TRANSCRIPTASE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2019-02-14 | — | — | WO | claimed |
| US-9487476-B2 | Catechol diethers as potent anti-HIV agents | YALE UNIVERSITY (US) | 2016-11-08 | — | — | US | claimed |
| US-20150105351-A1 | COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-04-16 | — | — | US | claimed |
| US-20140288017-A1 | CATECHOL DIETHERS AS POTENT ANTI-HIV AGENTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-09-25 | — | — | US | claimed |
| US-8513205-B2 | Potent chimeric NRTI-NNRTI bifunctional inhibitors of HIV-1 reverse transcriptase | YALE UNIVERSITY (US) | 2013-08-20 | — | — | US | claimed |
| WO-2013056003-A2 | CATECHOL DIETHERS AS POTENT ANTI-HIV AGENTS | YALE UNIVERSITY (US) | 2013-04-18 | — | — | WO | claimed |
| US-20110312880-A1 | POTENT CHIMERIC NRTI-NNRTI BIFUNCTIONAL INHIBITORS OF HIV-1 REVERSE TRANSCRIPTASE | ANDERSON KAREN S (US) | 2011-12-22 | — | — | US | claimed |
| WO-2009126293-A2 | POTENT CHIMERIC NRTI-NNRTI BIFUNCTIONAL INHIBITORS OF HIV-1 REVERSE TRANSCRIPTASE | YALE UNIVERSITY (US) | 2009-10-15 | — | — | WO | claimed |
| US-20050026902-A1 | Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents | PHARMACIA CORPORATION | 2005-02-03 | — | — | US | claimed |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| CN-110291087-B | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degrading agents | 阿尔维纳斯运营股份有限公司 | 2024-07-09 | — | — | CN | disclosed |
| US-11992531-B2 | C3-carbon linked glutarimide degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2024-05-28 | — | — | US | disclosed |
| CN-112262134-B | Cerebulin ligands and bifunctional compounds comprising same | 阿尔维纳斯运营股份有限公司 | 2024-05-24 | — | — | CN | disclosed |
| US-20100168190-A1 | Novel azoles and related derivatives as non-nucleoside reverse transcriptase inhibitors (nnrtis) in antiviral therapy (hiv) | YALE UNIVERSITY (US) | 2010-07-01 | — | — | US | disclosed |
| WO-2009126293-A2 | POTENT CHIMERIC NRTI-NNRTI BIFUNCTIONAL INHIBITORS OF HIV-1 REVERSE TRANSCRIPTASE | YALE UNIVERSITY (US) | 2009-10-15 | — | — | WO | disclosed |
| WO-2009005811-A1 | NOVEL AZOLES AND RELATED DERIVATIVES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NNRTIS) IN ANTIVIRAL THERAPY (HIV) | YALE UNIVERSITY (US) | 2009-01-08 | — | — | WO | disclosed |
| US-20050026902-A1 | Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents | PHARMACIA CORPORATION | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288017-A1 | CATECHOL DIETHERS AS POTENT ANTI-HIV AGENTS | COMT, NNMT, PNMT | ADRA2A 2371/4885ADORA3 3664/4885CHRM1 1921/4885 |
| US-20110312880-A1 | POTENT CHIMERIC NRTI-NNRTI BIFUNCTIONAL INHIBITORS OF HIV-1 REVERSE TRANSCRIPTASE | NAMPT, NAPRT, DNTT | ADRA2A 3636/4885ADORA3 2598/4885CHRM1 4048/4885 |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | ADRA2A 4442/4885ADORA3 3985/4885CHRM1 4416/4885 |
| US-11992531-B2 | C3-carbon linked glutarimide degronimers for target protein degradation | STUB1, UBE3C, UBE3A | ADRA2A 4338/4885ADORA3 3799/4885CHRM1 4310/4885 |
| US-20150105351-A1 | COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS | POLM, POLRMT, DHFR | ADRA2A 4001/4885ADORA3 2367/4885CHRM1 4115/4885 |
| US-20050026902-A1 | Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents | PTGS2, PTGS1, PTGES2 | ADRA2A 3559/4885ADORA3 1069/4885CHRM1 4537/4885 |
| US-20100168190-A1 | Novel azoles and related derivatives as non-nucleoside reverse transcriptase inhibitors (nnrtis) in antiviral therapy (hiv) | OXA1L, POLRMT, PNP | ADRA2A 4557/4885ADORA3 975/4885CHRM1 4761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.